Lilly to sell Lafayette plant to German firm

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. will sell its manufacturing plant in Lafayette to a German company in its first major move toward reducing its work force by 5,500 employees and cutting its operating expenses by $1 billion.

Indianapolis-based Lilly signed a nine-year contract with the buyer, Evonik Industries AG,  to supply Lilly with the active pharmaceutical ingredients the plant makes. Evonik will offer jobs to the nearly 700 full-time employees at the plant.

“The employees are the key to the success of this deal,” said Tom Bates, president of the North American region for Evonik, which is based in Essen, Germany. He said the company would offer comparable salaries and benefits to the employees.

Lilly did not disclose financial terms of the sale, but it will take an accounting charge of 23 cents per share, or about $264 million, in its third quarter financial report, which it will release on Oct. 21.

Some of those costs will come from giving severance packages to all the full-time employees dedicated to the Lafayette site. Lilly did not disclose the details of those packages.

About two dozen other employees who are not dedicated to the Lafayette site will relocate to Indianapolis. Also, about two dozen contract employees at the plant will not be offered jobs.

The sale is expected to close by the end of the year.

“This announcement today certainly support our goals of becoming a leaner and competitive company given the challenges the company faces,” said Lilly CEO John Lechleiter. Lilly announced its job and cost reduction goals on Sept. 14. It aims to achieve those goals by the end of 2011.

The plant near Lafayette, which is called the Tippecanoe Laboratories, currently makes active pharmaceutical ingredients for Lilly drugs Cialis, Cymbalta, Gemzar, Alimta and Tylan, an animal health product. It was founded in the 1950s to make large batches of antiobiotics.

Because today’s drugs come in smaller doses, the plant has been underutilized. Evonik plans to use that excess capacity to serve other drug companies, both large and small, Bates said.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ